Compare Eli Lilly And Co (LLY) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Newmont Corporation — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Eli Lilly And Co is far larger — about 8.5× Newmont Corporation's market cap, and Newmont Corporation pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Newmont Corporation for 58 Days on average.
| LLY | NEM | |
|---|---|---|
Market Cap | $1.04T | $121.75B |
Volume | 3,064,878 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $135.14 |
52-Week Low | $799.57 | $78.63 |
Typical Hold Time | 93 Days | 58 Days |
Enterprise Value | $1.09T | $118.34B |
Dividend Yield | 0.59% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Newmont Corporation (NEM) trades at $115.55, up 1.77% with strong fundamental performance including record free cash flow of $5.3B in H1 2026 and three consecutive earnings beats. The stock shows bearish technical signals despite solid valuation metrics with P/E of 14.57 and ROE of 25.53%. Recent news highlights operational improvements and gold price support driving per-share growth initiatives.
NEM presents a compelling value opportunity with strong analyst consensus (75.68% buy rating) and $136.83 price target representing 18% upside. Key risks include gold price volatility and execution of growth projects, but robust cash flow generation and improving margins support long-term shareholder value creation in the current gold market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
